Atopic dermatitis: Diagnosis, treatment, and aeromedical implications

Aviation Space and Environmental Medicine

Volumn 78, Issue 1, 2007, Pages 29-37

  Gates, Trina ^a,b  

^a Naval Aerospace Medicine Institute   (United States)

^b NONE   (United States)

Author keywords

Contact dermatitis; Hand dermatitis; Immunomodulators; Pimecrolimus; Rash; Skin; Tacrolimus; Topical corticosteroids

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; AZATHIOPRINE; CALCINEURIN; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; DOXEPIN; HYDROCORTISONE ACETATE; HYDROCORTISONE BUTYRATE; IMMUNOGLOBULIN E; IMMUNOMODULATING AGENT; PETROLATUM; PICIBANIL; PIMECROLIMUS; PSORALEN; TACROLIMUS; TAR;

ACNE; ADRENAL SUPPRESSION; AEROSPACE MEDICINE; AIRPLANE PILOT; ALCOHOL INTOLERANCE; ATOPIC DERMATITIS; BATH; CANCER RISK; CATARACT; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DIFFERENTIAL DIAGNOSIS; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; ENVIRONMENTAL FACTOR; ENVIRONMENTAL TEMPERATURE; FLU LIKE SYNDROME; FOLLICULITIS; GLAUCOMA; GROWTH RETARDATION; HEADACHE; HUMAN; HUMIDITY; HYPERESTHESIA; HYPERTENSION; HYPOPIGMENTATION; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; INTRAOCULAR HYPERTENSION; NEPHROTOXICITY; OCCUPATIONAL HAZARD; PERIORAL DERMATITIS; PHOTOTHERAPY; PURPURA; RASH; REBOUND; REVIEW; RISK FACTOR; RISK REDUCTION; ROSACEA; SIDE EFFECT; SKIN ATROPHY; SKIN BURNING SENSATION; SKIN IRRITATION; SKIN PAIN; SKIN PRURITUS; SKIN TINGLING; STRESS; STRIA; SWEATING; SYSTEMATIC REVIEW; TELANGIECTASIA; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; ULTRAVIOLET IRRADIATION;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; AEROSPACE MEDICINE; AVIATION; DERMATITIS, ATOPIC; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; TACROLIMUS;

EID: 33846044050     PISSN: 00956562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Ashcroft DM, Dimmock P, Garside R, et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomized controlled trials. Br J Med 2005; 330:516-22.
2. Beck LA. The efficacy and safety of tacrolimus ointment. J Am Acad Dermatol 2005; 53:S165-70.
3. Chapman MS, Lawerence A, Schachner MD, et al. Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate topic dermatitis. J Am Acad Dermatol 200; 53:S177-85.
4. Cookson WO, Moffatt MF. The genetics of atopic dermatitis. Curr Opin Allergy Clin Immunol 2002; 2:383-7.
5. Draelos Z, Nayak A, Pariser D, et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. J Am Acad Dermatol 2005; 53: 602-9.
6. rd ed. Philadelphia: Williams & Wilkins; 1997.
7. Ellis C, Luger T. International consensus conference on atopic dermatitis II (ICCADII): clinical update and current treatment strategies. B J Dermatol 2003; 148:S3-10.
8. Green C, Colquitt JL, Kirby J, Davidson P. Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once-daily vs. more frequent use. B J Dermatol 2005; 152:130-41.
9. Grunwald MH, Arnitai DB, Amichai B. Macrolactam immunomodulators (tacrolimus and pimecrolimus): new horizons in the topical treatment of inflammatory skin diseases. J Dermatol 2004; 31:592-602.
10. th ed. Philadelphia: Mosby Inc.; 2004.
11. Hanifin JM, Paller AS, Eichenfield L, et al. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol 2005; 53:S165-70.
12. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980; 92(Suppl.):44-7.
13. Holten KB. How should we care for atopic dermatitis? J Fam Pract 2005; 54:426-7.
14. Horiuchi Y. Topical streptococcal preparation OK432 for atopic dermatitis. J Dermatolog Treat 2005; 16:117-20.
15. Koo JYM, Fleischer MD, Abramovitis W, et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. J Am Acad Dermatol 2005; 53:S195-205.
16. Leung D, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Invest 2004; 113:651-7.
17. Lubbe J, Pournaras C, Saural JII. Eczema herpticum during treatment of atopic dermatitis with 0.1% tacrolimus ointment. Dermatology 2000; 201:249-51.
18. O'Neill PE. Common skin diseases: atopic dermatitis. In: Textbook of military medicine: military dermatology. Washington, DC: Office of the Surgeon General at TMM Publications; 2003: 564-8.
19. Paller AS, Lebwohl M, Fleischer AB, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J A Acad Dermatol 2005; 52:810-22.
20. rd ed. New York: Castle Connoly Graduate Medical Publishing; 2000:285-8.
21. Reitamo S, Ortonne JP, Sand F, et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005; 152:1282-9.
22. Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hyrdrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002; 109:547-55.
23. Reitamo S, Van Leent EJM, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109:539-46.
24. Shaw JC. Atopic dermatitis (eczema). Up To Date. Retrieved January 11, 2006, from http://www.uptodateonline.com/utd/ index.do.
25. Simpson D, Noble S. Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. Drugs 2005; 65:827-58.
26. Simpson EL, Hanifin JM. Atopic dermatitis. J A Acad Dermatol 2005; 53:115-28.
27. Trammell S, Shakil A. What is the role of tacrolimus and pimecrolimus in atopic dermatitis? J Fam Pract 2005; 54:714-6.
28. United State Air Force. Waiver guide: eczema/dermatitis. Retrieved March 31, 2006, from: http://www.brooks.af.mil/web/ consult_service/waiver%20guide/ html/Dermatology.htm.
29. United States Army. Aeromedical policy: atopic dermatitis. Retrieved March 31, 2006, from: http//usasam.amedd.army.mil/ _aama/policyLetter.htm.
30. United States Navy. Manual of the medical department: chapter 15, article 15-40, change 126. Washington, DC: Department of the Navy; 2005.
31. United States Navy. Naval Aerospace Medical Institute aeromedical reference and waiver guide. Retrieved March 31, 2006, from: http://www.nomi.med. navy.mil/NAMI/Waiver-GuideTopics/dermatology.htm.
32. Wallach D, Coste J, Tilles G, et al. The first images of atopic dermatitis: an attempt at retrospective diagnosis in dermatology. J Am Acad Dermatol 2005; 53:684-9.
33. Williams HC. Atopic dermatitis. N Engl J Med 2005; 352:2314-24.
34. Wilson LM, Reid CM. Molluscum contagiosum in atopic dermatitis treated with 0.1% tacrolimus ointment. Aust J Dermatol 2004; 45:184-5.
35. Wolff K, Stuetz A. Pimecrolimus for the treatment of inflammatory skin disease. Expert Opin Pharmacother 2004; 5:643-55.
36. Wooltorton E. Eczema drugs tacrolimus (protopic) and pimecrolimus (elidel): cancer concerns. CMAJ 2005; 172:1179-80.
37. Yoneda I. Probable decompression sickness in a trainee with atopic dermatitis. Aviat Space Environ Med 1998; 69:693-5.
38. Yones SS, Palmer RA, Hextall JM, Hawk LM. Exacerbation of presumed chronic actinic dermatitis by cockpit visible light in an airplane pilot with atopic eczema. Photodermatol Photoimmunol Photomed 2005; 21:152-3.